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Insulin resistance and loss of β-cell mass cause Type 2 diabetes (T2D). The objective of this study was to generate a nongenetic
mouse model of T2D. Ninety-six 6-month-old C57BL/6N males were assigned to 1 of 12 groups including (1) low-fat diet (LFD;
low-fat control; LFC), (2) LFD with 1 i.p. 40mg/kg BW streptozotocin (STZ) injection, (3), (4), (5), (6) LFD with 2, 3, 4, or 5
STZ injections on consecutive days, respectively, (7) high-fat diet (HFD), (8) HFD with 1 STZ injection, (9), (10), (11), (12) HFD
with 2, 3, 4, or 5 STZ injections on consecutive days, respectively. After 4 weeks, serum insulin levels were reduced in HFD mice
administered at least 2 STZ injections as compared with HFC. Glucose tolerance was impaired in mice that consumed HFD and
received 2, 3, or 4 injections of STZ. Insulin sensitivity in HFD mice was lower than that of LFD mice, regardless of STZ treatment.
Islet mass was not aﬀected by diet but was reduced by 50% in mice that received 3 STZ injections. The combination of HFD and
three 40mg/kg STZ injections induced a model with metabolic characteristics of T2D, including peripheral insulin resistance and
reduced β-cell mass.
1.Introduction
It is estimated that 23.6 million or 8% of the American
population suﬀers from diabetes [1]. Almost the same
numbers have prediabetes. While the availability of novel
drugs, techniques, and surgical intervention has improved
the survival rate of individuals with diabetes, the prevalence
of diabetes still rises in Americans, and the number of people
with diabetes is projected to double by 2025 [2]. These
alarming statistics underscore the need for research aimed
at discovering novel therapeutic strategies for the prevention
or treatment of this disease. For the study of Type 2 diabetes
(T2D)thereareavarietyofinbredmousestrainsthatserveas
popular models [3]. Genetic obese diabetic mice, including
leptin and leptin receptor knockouts (ob/ob and db/db,
resp.), are commonly used T2D models for developing new
treatments for this disease [3] .H o w e v e r ,T 2 Di sad i s e a s e
stemming from a combination of cumulative polygenic
traits and interactions with environmental stressors [4]. A
diet-induced model can be used to more closely resemble
the gradual progression from obesity to insulin resistance
and T2D, the hallmarks of the human phenotype [4]. The
development of a nongenetic mouse model for T2D involves
establishment of insulin resistance, a period of compen-
satory insulin release to maintain glucose homeostasis. The
pathogenesis of T2D then involves a combination of factors
includingdestructionofβcellsthatreducesinsulinsecretion,
hindering the body’s ability to maintain normoglycemia.
Because T2D is such a complex, heterogeneous disease
resultingfromacombinationofgeneticandlifestyle-induced
factors, there is unlikely to be a single model that best ﬁts all
T2D scenarios [5].
There have been multiple studies described that involve
the development of a C57BL/6 model of T2D [6]. Luo et al.
[6] started their study with 3-week-old mice and adminis-
tered a single injection of STZ at 100mg/kg BW after 3wk
of feeding a high-fructose, high-fat, or standard chow diet
to induce diabetes. T2D often occurs in middle- to older-
aged individuals. Therefore, a mouse model that closely
representsthephysiologicalstateprecedinginsulinresistance
and T2D may be more suitable for mimicking this human
disease. In addition, insulin resistance and hyperinsulinemia
manifestedaftertheonsetofobesityrepresentafundamental
aspect of T2D etiology [7]. Luo et al. [6] described two2 Experimental Diabetes Research
criteria for a suitable model of T2D: (1) metabolic proﬁle
matching the disease and (2) cost-eﬀectiveness. Several
groups [8, 9] used adult rats and several weeks of providing
a high-fat diet followed by a single, relatively high dose
of STZ injection to induce a model of T2D. In a recent
publication we demonstrated that ﬁve consecutive low doses
(40mg/kg BW) of STZ triggered mild to moderate diabetes
in young mice fed standard rodent chow by causing gradual
destruction of pancreatic β cells [10]. Given this observation
and our hypothesis that pancreatic β cells in obese mice
are more susceptible to environmental factor-induced injury,
we developed a method to generate a nongenetic model of
T2D using older obese mice. We employed a combination
of feeding a high-fat diet and administering consecutive
multiplelowdosesofSTZinjection,withoutcausingdiabetes
instandardchow-fedmice.Thisprotocolresultsinagradual,
partial destruction of pancreatic β cells in high fat-fed,
insulin-resistant mice without signiﬁcant eﬀect on islets in
chow-fed mice, more closely resembling the features of T2D
in humans.
2.MaterialsandMethods
2.1. Animals and Study Design. The following animal pro-
cedures were reviewed and approved by the institutional
animal care and use committee at Virginia Polytechnic Insti-
tute and State University. All chemicals were purchased from
Sigma Aldrich (St. Louis, MO) unless otherwise stated. Diets
were purchased from Research Diets Inc. (New Brunswick,
NJ). Male C57BL/6NCr (NCI Frederick) mice (6mo. old)
were obtained and housed individually in standard-sized
cages(29 × 14 × 13cm)arrangedin adouble-faced 140-cage
ventilation rack in a temperature and humidity controlled,
pathogen-free room on a 12h light cycle (6am to 6pm) with
free access to food and water. A randomized complete block
design was used to assign 96 mice to one of 12 groups with
fasting blood glucose (FBG) as the blocking factor. Mean
FBG and body weight (BW) after assignment to groups was
114.38mg/dL and 28.08g, respectively. Body composition
was evaluated before the start of the trial using an LF-90
instrument (Bruker Optics, Inc., Billerica MA). The LF-90
body composition instrument is based on Time Domain
Nuclear Magnetic Resonance (TD-NMR) technology which
provides an in vivo measurement of lean tissue, body fat, and
body ﬂuid in live mice and rats without anesthesia. Mean
lean, fat and ﬂuid percentages were similar among groups
(means of 72.74 ± 2.2, 13.36 ± 2.8, and 7.37 ± 0.38%, resp.).
Mice were oﬀered either a standard rodent chow containing
10% of kcal as fat (low-fat diet; LFD) or a diet containing
60% kcal as fat, primarily in the form of saturated fat from
lard (high-fat diet; HFD; Table 1) ad libitum. Mice received
an intraperitoneal (i.p.) injection of vehicle (0.05M citrate
buﬀer, pH 4.5; non-STZ LFD and HFD controls) or 1, 2, 3, 4,
or 5 doses of STZ dissolved in the vehicle at 40mg/kg BW
per dose. Streptozotocin was prepared fresh each day and
multiple doses were administered on consecutive days. At
1wk following the ﬁrst injection, FBG levels were measured.
At2and3wkfollowingtheﬁrstinjection,aglucosetolerance
test (GTT) and insulin tolerance test (ITT) were performed,
Table 1: Ingredient and chemical composition of diets.
Standard chow High-fat chow
Ingredient Amt (g) Kcal Amt (g) kcal
Casein, 80 mesh 200 800 200 800
L - C y s t i n e 31 231 2
Corn starch 315 1260 0 0
Maltodextrin 10 35 140 125 500
Sucrose 350 1400 68.8 275.2
Cellulose, BW200 50 0 50 0
Corn oil 25 225 25 225
Lard 20 180 245 2205
Mineral mix, S10026 10 0 10 0
Dicalcium phosphate 13 0 13 0
Calcium carbonate 5.5 0 5.5 0
Potassium citrate, 1H20 16.5 0 16.5 0
Vitamin mix, V10001 10 40 10 40
Choline bitartrate 2 0 2 0
FD&C yellow dye #50 . 0 5 0 0 0
FD&C red dye #40 0 0 0.05 0
Gm (%) Kcal (%) Gm (%) Kcal (%)
P r o t e i n 1 92 02 62 0
Carbohydrate 67 70 26 20
Fat 4 10 35 60
Kcal/gram 3.8 5.2
respectively. At 4wk following STZ injections, FBG was
measured, as well as body composition, and animals were
euthanized by CO2 asphyxiation after an overnight fast.
Blood was collected from the orbital sinus into heparin-
coated capillary tubes to prevent clotting, and the remainder
was collected in microcentrifuge tubes and allowed to clot
on ice. The intra-abdominal fat pad, liver, and pancreas were
surgically removed from the mouse, rinsed in ice-cold PBS
and weighed. The pancreas was divided into the “head”
portion (adjacent to the duodenum) and the remainder
(“body”) was divided into 3 equal portions. Tissues were
ﬁxed in 10% neutral-buﬀered formalin. Pancreas samples
were sent to AML Laboratories (Rosedale, MD) for paraﬃn-
embedding, sectioning, and mounting on glass slides. Three
sections were made for each tissue sample, such that there
were 12 total sections per pancreas. Slides were stained with
hematoxylin and eosin and used for measurement of islet
mass
2.2. Blood Lipid and Hormone Proﬁle Parameters. Total cho-
lesterol was immediately measured from total blood follow-
ing euthanasia using a CardioChek blood analyzer (Polymer
Technology Systems, Indianapolis, IN; PTS). Clotted blood
samples were centrifuged at top speed for 10min. The super-
natant was transferred to a new tube and centrifuged at top
speed for an additional 5min. The supernatant was collected
and transferred to a 96-well plate for storage at −80◦C.
Serumwasusedformeasuringinsulinusinganultrasensitive
mouse/rat insulin ELISA (Mercodia, Inc., Uppsala, Sweden).Experimental Diabetes Research 3
Supernatants from centrifuged blood collected with hep-
arinizedcapillaries(plasma)usedformeasuringtriglycerides
and HDL with the CardioCheck analyzer and appropriate
test strips. Randomly selected plasma samples were used
to determine cholesterol levels and to recalculate HDL and
triglycerides on a whole blood basis. The HDL levels were
calculated using the Friedewald equation: [LDL-Cholesterol
= Total Cholesterol–(HDL-Cholesterol + Triglycerides/5)],
with all concentrations presented as mg/dL.
2.3. Fasting Blood Glucose, Glucose Tolerance Test (GTT), and
Insulin Tolerance Test (ITT). At 2, 4, 6, 7, 8, and 9wk, 16-h
FBG levels were measured in whole blood drawn from the
tail vein using an ultrasensitive hand-held glucometer (The
Kroger Co., Cincinnati, OH). Both the glucose and insulin
tolerance tests were performed following a 16h fast with
baseline blood glucose measurements taken immediately
before beginning the test. Blood glucose measurements were
taken by a single person to eliminate potential operator
variability. For the GTT, glucose was delivered via i.p.
i n j e c t i o na tad o s eo f2g· kg
−1 B Wi nav o l u m eo f0 . 1m L
water. Blood glucose levels were measured at 15, 30, 60,
and 120min after injection. For the ITT, human insulin was
administered via i.p. injection at a dose of 0.75U · kg
−1 BW.
Bloodglucoselevelsweremeasuredat15,30,60,and120min
after injection as described for GTT test.
2.4. Islet Mass and Density. Histological evaluation was
performed in 4 groups of mice: (1) control mice that
consumed LFD, (2) mice that consumed LFD and received
3 injections of STZ, (3) control mice that consumed HFD,
and (4) mice that consumed HFD and received 3 injections
of STZ. Islet mass was determined using point counting
stereology [11] on hematoxylin and eosin-stained slides.
A 100-square grid reticle (0.1mm per square) was used
to count points over islet tissue using an Olympus BX51
microscope and a 10x magniﬁcation. The area occupied by
islets was expressed as a ratio to the total area of pancreatic
tissueontheslideandmultipliedby100todeterminerelative
islet volume percentage. Islet mass was calculated as the
relative volume of islets multiplied by the total weight of the
pancreas. Images of all sections were acquired with a CCD
camera and analyzed using Image J software to determine
pancreas area on the slide. The area (mm2)v a l u e sw e r e
generated automatically. Relative islet volume was analyzed
to compare the head region to the body of the pancreas and
to evaluate total volume of the entire pancreas tissue.
2.5. Statistical Analysis. T h eP r o cU n i v a r i a t ep r o c e d u r eo f
SAS was used to test for normality, and data were trans-
formed to normalize variances using a transformation
selector as previously described [12]. All data were analyzed
usingtheProcMixedprocedureofSAS(Cary,NC).Analpha
level of P<0.05 was considered statistically signiﬁcant. For
the glucose tolerance and insulin tolerance tests, incremental
area under the curve and total area under the curve (AUC)
was calculated. Incremental AUC were calculated as the sum
of blood glucose measurements for two consecutive time
points multiplied by the time interval and then divided by
two (trapezoidal rule). The glucose clearance rate was also
calculated for each animal from the glucose tolerance test
data by determining the slope of the line (m = (y1−
y2) · (x1 −x2)
−1) for blood glucose measurements between
30 and 120min. This calculation was based on the assump-
tion that the blood glucose levels of “normal” lean mice
will peak at 30min post-glucose loading, thus, clearance
rates can be determined from the slope of the line between
30 and 120min [5]. The model for the GTT AUC, ITT
AUC, body composition before and after STZ, and blood
hormone and lipid proﬁle parameters collected on the day
of euthanasia included the main eﬀects of diet and STZ
treatment and the 2-way interaction. Orthogonal linear
contrasts were used to further test for signiﬁcant diﬀerences.
Contrast coeﬃcients were generated to compare the control
to the treated within each diet and to compare each low-
f a tg r o u pw i t hi t sr e s p e c t i v eh i g h - f a tg r o u p .M o u s en e s t e d
within diet × STZ treatment was designated in the model
as a random eﬀect and used as the error term. The raw
GTT and ITT data, as well as the fasting blood glucose,
BW and feed intake data that were collected longitudinally,
were summarized as least squares means with SEM plotted
over time, and the statistical model included the main eﬀects
of diet, STZ treatment and time, and 2-way interactions,
with time as a repeated measure. For each variable analyzed,
mouse nested within diet × STZ treatment was subjected to
atleast3covariancestructuresincludingautoregressiveorder
1, unstructured covariance and compound symmetry. For all
variables, the Akaike’s information criterion was closest to
zero using the autoregressive order 1 covariance structures,
and thus, it was used for each analysis with the Kenward-
Roger adjustment method for approximation of degrees of
freedom. The model for relative islet volume also included
pancreas region (head versus body) as a main eﬀect.
3. Results
3.1. Food Intake, Body and Organ Weight, and Body Com-
position. Feed intake data are shown in Figure 1. During
the ﬁrst week following STZ injections, feed intake was
reduced in mice that consumed the HFD as compared
with the noninjected mice that consumed HFD (P<0.01;
Figure 1(a)). After the ﬁrst week post-STZ, food intake was
not diﬀerent among the STZ-injected and non-STZ injected
mice, regardless of diet. Mice that consumed HFD and
received 3, 4, or 5 injections of STZ ate signiﬁcantly less
(P<0.01) than the respective LFD groups (Figure 1(b)).
After 5wk of ad libitum feeding but before STZ injec-
tions, mice that consumed the HFD were heavier than mice
thatconsumedtheLFD(41.7±3.8versus33.5g ±2.8,resp.).
During the ﬁrst week that followed STZ injections, BW
decreased in response to STZ injections and the decrease was
most accentuated in mice that received the most injections of
STZ (Figure 2(a)). Injection of STZ had no eﬀect on BW in
mice that consumed the LFD, whereas mice that consumed
HFD and received 4 or 5 injections of STZ weighed less (P<
0.04) than the respective control mice. Mice that consumed4 Experimental Diabetes Research
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Figure 1: Food intake. (a) Food intake (A; g·mouse−1 ·d
−1)b e f o r e
beginning STZ injections (end of wk 5) and each week until the end
of the trial (9wks) and (b) interaction of diet × STZ treatment on
food intake. Male, retired breeder (6mo.) C57BL/6 mice were used
for this study. Before STZ injections N = 8 and after STZ injections
N = 5–8.Valuesrepresentmean ±SEM. #P<0.05 versus respective
LFD group, ‡P = 0.07 versus respective LFD group.
HFD and received 1, 2, or 5 injections of STZ weighed more
than their LFD-fed counterparts (P<0.04), while there was
no signiﬁcant diﬀerence among LFD and HFD mice that
r e c e i v e d3o r4i n j e c t i o n s .
The abdominal fat pad, both as an absolute weight and
as a percentage of BW, was diﬀerent among groups (P =
0.0001), and speciﬁcally, was greater (P<0.05) in mice that
consumed HFD, regardless of STZ treatment, compared with
mice that consumed LFD (Figures 3(a) and 3(b)). In mice
that consumed LFD, 4 or 5 STZ injections reduced the fat
pad weight, both as an absolute weight and as percentage
of BW (P<0.0 5 ) .I nm i c et h a tc o n s u m e dH F D ,4o r5
STZ injections reduced absolute fat pad weight but had no
eﬀect on relative fat pad weight. The pancreas weights and
relative pancreas weights were diﬀerent among treatment
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Figure 2: Body weights: (a) Body weights before beginning STZ
injections (end of wk 5) and each week until the end of the trial
(9wks) and (b) interaction of diet and STZ treatment on BW. Male,
retired breeder (6mo.) C57BL/6 mice were used for this study.
Before STZ injections N = 8 and after STZ injections N = 5–8.
Values represent mean ± SEM. ∗P<0.05 versus respective control,
#P<0.05 versus respective LFD group.
groups as well (P = 0.002 and P = 0.04, resp.). The weight
of the pancreas was not diﬀerent among mice that consumed
LFD (Figure 3(c)), but when expressed relative to BW was
increased in mice that received 4 or 5 injections of STZ
(Figure 3(d)) .T h ep a n c r e a sw e i g h tw a sg r e a t e ri nm i c et h a t
consumed HFD and received 1 injection of either vehicle or
STZ, as compared with the respective LFD-fed group (P<
0.0 5 ) .M i c et h a tc o n s u m e dH F Da n dr e c e i v e d5i n j e c t i o n so f
STZ exhibited reduced pancreas weights as compared with
HFD controls (P<0.05) and when expressed relative to BW
showed reduced weights as compared with the LFD group
thatreceived5injectionsofSTZ(P<0.05).Theliverweights
andrelativeliverweightswerealsodiﬀerentamongtreatment
groups (P = 0.003 and P = 0.0001 for interaction of diet ×
STZtreatment,resp.).TheweightoftheliverwasnotaﬀectedExperimental Diabetes Research 5
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Figure 3: Organ weights: (a) Intra-abdominal fat pad weights as absolute values and (b) as percentages of BW on ﬁnal day of trial. (c)
Pancreas weight as absolute value and (d) as percentage of BW on ﬁnal day of trial. (e) Liver weight as absolute value and (f) as percentage
of BW on ﬁnal day of trial. Male, retired breeder (6 mo.) C57BL/6 mice were used for this study. Values represent mean ± SEM (N = 5–8).
∗P<0.05 versus respective control, #P<0.05 versus respective LFD group, ‡P = 0.07 versus respective LFD group, †P = 0.05 versus
respective control.
by STZ in mice that consumed LFD (Figure 3(e))b u tw h e n
expressed proportionally to BW was greater (P<0.05) in
micethatreceived3,4,or5injectionsofSTZ(Figure3(f)).In
mice that consumed the HFD and received 4 or 5 injections
of STZ, the absolute weight of the liver was greater (P<
0.05) as compared with the HFD controls, however, when
expressed as a ratio to BW, there were no diﬀerences among
mice that consumed HFD. Mice that consumed HFD and
received 4 injections of STZ had greater (P<0.05) liver
weights as compared with the respective LFD-fed group, and
when liver was expressed relative to BW, the liver was bigger
in mice that consumed LFD and either received the vehicle
or up to 3 injections of STZ, as compared with the respective
g r o u po fm i c et h a tc o n s u m e dH F D .
Body composition reﬂected feed intake and BW data
and was signiﬁcantly altered by STZ treatment. After 1mo.
of feeding, the mean fat tissue, lean tissue, and body ﬂuid
percentages for the mice that consumed HFD and LFD were6 Experimental Diabetes Research
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Figure 4: Body composition after STZ: (a) Fat tissue percentage, (b) lean tissue percentage, and (c) ﬂuid percentage of body composition
during the ﬁnal week of trial. Male, retired breeder (6 mo.) C57BL/6 mice were used for this study. Values represent mean ± SEM (N = 5–
8). ∗P<0.05 versus respective control, #P<0.05 versus respective LFD group, ‡P = 0.06 versus respective LFD group, †P = 0.07 versus
respective control.
23.7 ± 0.74 and 14.01 ± 0.77, 60.58 ± 0.67 and 70.24 ±
0.91, and 8.56 ± 0.08 and 7.57 ± 0.15, respectively. After
4wk of STZ treatment, fat tissue percentage was reduced
(P<0.05) in mice that were administered 4 or 5 injections of
STZandconsumedeithertheLFDorHFD,incomparisonto
the control animals (Figure 4(a)). Lean percentage increased
in mice that consumed the LFD and were administered 4
injectionsofSTZ(Figure4(b)).InmicethatconsumedHFD,
the eﬀect was more pronounced and mice that received 2, 3,
4, or 5 injections of STZ displayed increased (P<0.05) lean
tissue percentages. Fluid percentage decreased (P<0.05) in
mice that consumed LFD and received at least 3 injections
of STZ, in comparison to the controls, and in mice that
consumed HFD and received at least 4 injections of STZ
(Figure 4(c)).
3.2. Fasting Blood Glucose. Fasting blood glucose levels were
m e a s u r e da f t e r2 ,4 ,6 ,7 ,8 ,a n d9 w ko ft h es t u d y( F i g -
ure 5(a)). After 4wk of feeding and before injection of STZ,
fasting blood glucose levels were not signiﬁcantly diﬀerent
between LFD- and HFD-fed mice (89.2 ± 19.7 versus 104.1
± 20.0mg/dL, resp.). In response to STZ,however, the dif-
ferences in fasting blood glucose levels became accentuated
(P = 0.0001) and mice that consumed the LFD were more
resistant to the eﬀects of STZ. In the ﬁrst wk following
the start of STZ injections, only mice that received at least
3 injections of STZ and consumed HFD displayed fasting
blood glucose levels that were signiﬁcantly diﬀerent from the
HFD controls (P<0.01; Figure 5(b)). Mice that received
at least 3 injections of STZ and consumed the HFD also
had greater fasting blood glucose levels than the respective
LFD group (P<0.05). Over the 4wk period that followed
STZ injections, mice that consumed LFD and received 4 or 5
injections of STZ displayed fasting blood glucose levels that
were diﬀerent from the LFD-fed control (P<0.05).
3.3. Glucose Tolerance. The glucose tolerance test data were
analyzed as total AUC and glucose clearance rate between 30
and 120min. Means and standard errors plotted over time
are shown in Figure 6(a), and AUC and glucose clearance
rate data are illustrated in Figures 6(b) and 6(c),r e s p e c t i v e l y .
There was a greater AUC for mice that consumed either the
LFD or HFD and received 4,5 or 2, 3, 4, or 5 injections,
respectively, of STZ as compared with the respective control
mice(P<0.05).TheAUCwasgreaterinmicethatconsumed
HFD and received 3 (P<0.05) or 4 (P = 0.06) injections
ofSTZascomparedtotherespectiveLFDgroup.Theglucose
clearance rate was substantially reduced by STZ treatmentExperimental Diabetes Research 7
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Figure 5: Fasting blood glucose concentrations: (a) Fasting blood
glucose concentration before beginning STZ (end of wk 2) and
each week until the end of the trial (9wks) and (b) interaction of
diet and STZ treatment on fasting blood glucose concentrations.
Male, retired breeder (6mo.) C57BL/6 mice were used for this
study. Values represent mean ± SEM (N = 5–8). ∗P<0.05 versus
respectivecontrol, #P<0.05versusrespectiveLFDgroup, ‡P = 0.08
versus respective LFD group, †P = 0.08 versus respective control.
(P = 0.0001; Figure 6(c)). In mice that ate the LFD and
received 5 injections of STZ, glucose clearance rate was
reduced (P = 0.001). The HFD magniﬁed the eﬀects of STZ
on glucose clearance. In mice that consumed the HFD, 3
low doses of STZ is suﬃcient to signiﬁcantly impair glucose
clearance rate (P<0.01), but 5 injections of STZ is required
to reduce glucose clearance rate (P = 0.02) in mice that
consumed LFD.
3.4. Insulin Tolerance. The insulin tolerance test data were
also analyzed as total AUC. Means and standard errors
plotted over time are shown in Figure 7(a) and total AUC
in Figure 7(b). The AUC was aﬀected by diet and STZ
treatment (P = 0.0001). Mice fed HFD had signiﬁcantly
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Figure 6: Glucose tolerance test: (a) Fasting blood glucose concen-
trationsatbaselineand15,30,60,and120minpost-glucoseloading
via i.p. injection (2g · kg
−1 BW), (b) interaction of diet and STZ
treatment on total AUC calculated from glucose tolerance test data,
(c) interaction of diet and STZ treatment on glucose clearance rate,
calculated from 30 to 120min post-glucose loading. Male, retired
breeder (6mo.) C57BL/6 mice were used for this study. Values
represent mean ± SEM (N = 5–8). ∗P<0.05 versus respective
control, #P<0.05 versus respective LFD group, ‡P = 0.06 versus
respective LFD group, †P = 0.06 versus respective control.8 Experimental Diabetes Research
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Figure 7: Insulin tolerance test: (a) Fasting blood glucose concen-
trationsatbaseline and15, 30,60, and120minpost-insulinloading
via i.p. injection (0.75U · kg
−1 BW), (b) interactions of diet ×
STZ treatment on total AUC calculated from insulin tolerance test
data. Male, retired breeder (6mo.) C57BL/6 mice were used for this
study. Values represent mean ± SEM (N = 5–8). #P<0.05 versus
respective LFD group.
higher AUC that those treated with LFD (P<0.05). There
was a greater AUC in mice that consumed either the LFD or
HFD and received at least 3 injections of STZ, as compared
with the respective control group (P<0.05), suggesting
that STZ treatment may partially cause insulin intolerance
in these animals. With the exception of mice that received 1
injection of STZ, the total AUC for all groups of mice that
consumed HFD was greater (P<0.05) than the AUC for
the respective groups of mice that ate the LFD. These data
indicate that HFD treatment for 4wks can adequately induce
insulin resistance in older adult mice.
3.5. Blood Lipid Proﬁle and Hormone Parameters. At 4wk
after STZ, total blood cholesterol levels were greater (P<
0.05) in mice that consumed the HFD and received 4 or
5 injections of STZ as compared with the respective LFD
groups (Figure 8(a)). There tended (P = 0.07) to be greater
cholesterol levels in mice that consumed HFD and received
3 injections as compared with the respective LFD group. The
total blood HDL levels were greater (P<0.05) in mice that
consumed HFD and received 5 STZ injections as compared
with the HFD controls (Figure 8(b)). Mice that consumed
HFD and received 1, 2, 4, or 5 injections of STZ displayed
greater (P<0.05) HDL concentrations than the respective
L F Dg r o u p s ,a n dm i c et h a tc o n s u m e dH F Da n dr e c e i v e d3
injections of STZ tended (P = 0.08) to have greater HDL
blood concentrations than the respective LFD group. Mice
that ate the HFD and received 4 or 5 injections of STZ
displayed greater (P<0.03) blood triglyceride levels in the
blood as compared with the respective mice that were fed
the LFD diet. Total blood triglyceride levels were reduced
(P<0.04) in mice that consumed LFD and received 4 or
5 doses of STZ, as compared with the controls (Figure 8(c)).
Consistent with developing insulin resistance in HFD-
fed mice, the blood insulin levels in HFD-fed mice were
about threefold of those in LFD control mice (P = 0.001),
suggesting that treatment of older adult mice with HFD
for 4wks can induce hyperinsulinemia, a metabolic feature
during the pathogenesis of T2D. In HFD mice, at least 2
injections of STZ were needed to reduce serum insulin levels
(P = 0.001) as compared with HFD controls, whereas
4 consecutive injections of STZ were required to cause
signiﬁcant reductions in circulating insulin (P = 0.006) in
mice that consumed the LFD (Figure 8(d)).
3.6. Relative Islet Volume and Total Islet Mass. Islet volume
and mass were determined in control mice that consumed
either LFD or HFD and mice that consumed either diet
a n dr e c e i v e d3i n j e c t i o n so fS T Z .T h e r ew a sa p p r o x i m a t e l y
6.5 times greater volume of islets in the body region of
the pancreas as compared with the head. While there was
little diﬀerence in volume of islets in the head region of the
pancreas among treatment groups, there was approximately
a 50% reduction in islet volume in the body of the pancreas
inresponseto3injections ofSTZ(Figure9(a)).Consistently,
total islet mass was reduced by about the same percentage
in mice that received 3 injections of STZ than mice that
consumed either the LFD or HFD.
4. Discussion
While peripheral insulin resistance is common during obe-
sity and aging in mice and people, progression to T2D is
largely due to insulin secretory dysfunction and signiﬁcant
apoptosisoffunctionalβ cells [13–17],leadingtoaninability
to compensate for insulin resistance. As such, regeneration
and preservation of functional β-cell mass becomes one
of the fastest growing areas in diabetes research. While
promotion of β-cell mass has been consistently shown as
a promising strategy to treat diabetes [13, 14, 18–21], the
majority of these studies have been carried out with obese
diabetic (db/db) mice at relatively young ages. However,Experimental Diabetes Research 9
L
F
L
F
-
1
L
F
-
2
L
F
-
3
L
F
-
4
L
F
-
5
H
F
H
F
-
1
H
F
-
2
H
F
-
3
H
f
-
4
H
F
-
5
Treatment group
100
120
140
160
180
W
h
o
l
e
b
l
o
o
d
t
o
t
a
l
c
h
o
l
e
s
t
e
r
o
l
(
m
g
/
d
L
)
0
80
60
40
20
# #
‡
(a) Whole blood total cholesterol
L
F
L
F
-
1
L
F
-
2
L
F
-
3
L
F
-
4
L
F
-
5
H
F
H
F
-
1
H
F
-
2
H
F
-
3
H
f
-
4
H
F
-
5
Treatment group
100
120
140
160
0
80
60
40
20
# # #
#
∗
W
h
o
l
e
b
l
o
o
d
H
D
L
(
m
g
/
d
L
)
‡
(b) Whole blood HDL
L
F
L
F
-
1
L
F
-
2
L
F
-
3
L
F
-
4
L
F
-
5
H
F
H
F
-
1
H
F
-
2
H
F
-
3
H
f
-
4
H
F
-
5
Treatment group
#
∗ ∗
#
50
30
W
h
o
l
e
b
l
o
o
d
t
r
i
g
l
y
c
e
r
i
d
e
s
(
m
g
/
d
L
)
10
0
60
40
20
†
(c) Whole blood triglycerides
L
F
L
F
-
1
L
F
-
2
L
F
-
3
L
F
-
4
L
F
-
5
H
F
H
F
-
1
H
F
-
2
H
F
-
3
H
f
-
4
H
F
-
5
Treatment group
#
∗
∗
#
∗
∗ ∗
0
0.5
1
1.5
2
2.5
S
e
r
u
m
i
n
s
u
l
i
n
(
n
g
/
m
L
)
†
(d) Serum insulin
Figure 8: Interactions of diet × STZ treatment on blood lipid proﬁle and hormones on ﬁnal day of trial. (a) Whole blood total cholesterol,
(b) whole blood HDL, (c) whole blood triglycerides, and (d) serum insulin levels. Male, retired breeder (6mo.) C57BL/6 mice were used for
this study. Values represent mean ± SEM (N = 5–8). ∗P<0.05 versus respective control, #P<0.05 versus respective LFD group, ‡P = 0.07
to 0.08 versus respective LFD group, †P = 0.06 to 0.07 versus respective control.
recent studies indicated that the capacity of β-cell regenera-
tion is very limited in early middle-aged and older mice [22,
23], which raises an important question on the suitability
of using young rodents to assess β-cell regeneration-based
therapies for human T2D that occurs mostly in middle-aged
and older individuals. In the present study, we generated
a nongenetic mouse model of T2D using early middle-
aged mice by feeding an HFD followed by multiple low
doses of intraperitoneal STZ administration that did not
cause diabetes in chow-fed mice. Like db/db mice, which
is an expensive genetic obese diabetic mouse model, this
mouse model shares the metabolic characteristics of human
T2D, with peripheral insulin resistance and reduced β-cell
mass and function [6, 24, 25]. However, unlike the db/db
mice that develop overt and often severe diabetes at a very
young age (4–8wks) [3], a condition and age that are not
closely pertinent to humans developing this disease, the
diabetic model reported herein, which was generated with
mice at 6 month of age, develops mild to moderate diabetes,
a n dt h e r e f o r em a yb em o r es u i t a b l ea saT 2 Dm o d e lf o r
developing eﬀective treatments and preventative strategies.
In addition, the use of low doses of STZ in high fat-fed mice
will also minimize the variability of diet-induced diabetes
development and therefore provide better experimental
controls for evaluating diabetic treatment strategies.
As expected, mice that consumed the HFD were heavier
than mice fed LFD and displayed slightly lower food intakes,
presumably due to the greater caloric density of the high-fat
diet. Injection of STZ slightly reduced food intake during the
ﬁrst few days but in general intakes ﬂuctuated in a similar
manner and remained relatively stable over the next 4wk,
with mice consuming more LFD as compared with mice that
atetheHFD.Fouror5injectionsofSTZreducedBWandthe
fat composition of mice that consumed HFD and reduced
the weight of abdominal fat although it did not aﬀect the
weight of abdominal fat as a percentage of BW. In mice that
consumed LFD however, there was a reduction in both fat
composition and fat pad, both as an absolute weight and as
proportion of BW, in response to 4 or 5 injections of STZ,
which is also logical given that there was no eﬀect of STZ
on BW in those mice. The reductions in BW and body fat
in severely diabetic mice (4 or 5 injections of STZ) occurred
without a diﬀerence in food intake between these mice and
mice from the other groups that consumed HFD.
Blood lipid proﬁle was inﬂuenced in this study by high-
fatfeedingandbySTZinjection.Dyslipidemia,characterized10 Experimental Diabetes Research
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Figure 9: Relative islet volume and total islet mass on the ﬁnal
day of the trial. (a) Relative islet volume and (b) total islet mass.
Male, retired breeder (6mo.) C57BL/6 mice were used for this
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by elevated blood cholesterol, triglycerides, phospholipids,
and changes in lipoprotein composition, is a characteristic
feature of T2D [26]. We observed a general trend that high-
fat feeding and STZ injection resulted in elevated HDL and
that total cholesterol and triglyceride levels were elevated
in mice that ate the HFD and received 4 or 5 injections of
STZ. Others have reported an inﬂuence of STZ injection on
blood cholesterol, lipoprotein, and triglyceride concentra-
tions [9, 27]. This could be due to elevated chylomicron and
endogenousLDLformationasaresultofconsuminganHFD
[9, 27]. While changes in these blood measurements tend to
precedeT2D,wedidnotobservesigniﬁcantchangesinblood
lipid proﬁle in mice consuming the HFD without receiving
STZ injections, suggesting that dyslipidemia in diabetic mice
was modulated in part by the STZ. Others suggested that
STZ leads to increased intestinal absorption and synthesis of
cholesterol [9, 27]. STZ has a high aﬃnity for the glucose
transporter 2 (GLUT2) which is highly expressed in both the
small intestine and pancreas, indicating that STZ could lead
to changes in intestinal function [28].
While FBG levels vary among mouse strains and tend
to be greater than those observed in humans, FBG at least
250mg/dL is considered diabetic in mice [3]. The mice that
consumed HFD and received either the vehicle or 1 injection
of STZ displayed hyperinsulinemia without impaired FBG,
characteristic of the metabolic state preceding T2D in
humans whereby the individual is still able to maintain
blood glucose homeostasis. While injection of 2 doses of STZ
impaired glucose tolerance and greatly attenuated the HFD-
induced hyperinsulinemia which is apparently required to
counteract peripheral insulin resistance in these mice, HFD-
fed animals treated with these STZ doses still had normal
FBG, suggesting that this amount of STZ is still inadequate
in destroying pancreatic β-cell mass to such an extent that
animals become diabetic.
Mice that consumed the HFD and received at least
3 injections of STZ maintained FBG levels greater than
250mg/dL during the ﬁnal 3wk of the trial. However, mice
that consumed the low-fat diet and received 5 injections
o fS T Zd i s p l a y e dF B Gl e v e l st h a tp e a k e da tg r e a t e rt h a n
250mg/dL during the 8th week of the trial. While mice
that received 4 or 5 injections of STZ showed FBG levels
greater than controls, regardless of diet, the HFD magniﬁed
the eﬀect of the STZ, and mice that consumed HFD and
received at least 3 injections of STZ displayed FBG levels
that were greater than the respective mice that consumed
LFD, indicating that feeding of an HFD and establishment
of insulin resistance preceding diabetes enhances the action
oftheSTZ.Weobservedreducedseruminsulinlevelsinmice
t h a tr e c e i v e da tl e a s t2i n j e ct i o n so fS T Za n dc o n s u m e dH F D ,
as compared with the controls, and mice that consumed
LFD and received 4 injections also showed reduced levels
of circulating insulin, and those that received 5 injections
had insulin levels that were not signiﬁcantly lower although
numerically lower than the controls.
A glucose tolerance test was performed at 2wk after STZ
and insulin tolerance test at 3wk after STZ. Impaired glucose
tolerance was observed in mice that consumed HFD and
received at least 2 injections of STZ. In mice that consumed
HFD and received only 1 injection of STZ it is clear, judging
from the data, that glucose tolerance is maintained in these
animals by their ability to secrete suﬃcient quantities of
insulin to compensate for impaired insulin resistance. In
mice that consumed the LFD and received 4 or 5 injections
of STZ, glucose tolerance was impaired, which is primarily
due to destruction of pancreatic islets. However, feeding the
HFD accentuated the diﬀerences. Evaluation of the glucose
clearance rate showed that ability of mice to clear glucose
from the blood after glucose levels reached peak values
(30min) was impaired in mice that consumed HFD and
received at least 3 injections of STZ. Mice that consumed
the LFD and received 5 injections of STZ showed a similar
phenomenon. Because eﬀects among mice that received 4
or 5 injections of STZ were so similar, regardless of diet,
it appears that 4 and most deﬁnitely 5 injections of STZ
at 40mg/kg BW have an overly destructive eﬀect in theExperimental Diabetes Research 11
pancreas. These data are in keeping with the idea that β-cell
dysfunction preceded diabetes induced by STZ injection in
mice that consumed the HFD.
Insulin sensitivity was inﬂuenced by the HFD alone and
was more dramatically inﬂuenced by the combination of diet
and STZ treatment. With the exception of mice that received
1 injection of STZ, all mice that consumed HFD displayed
increased AUC as compared with mice that consumed LFD,
demonstrating impairment in insulin sensitivity, indepen-
dent of STZ treatment. The signiﬁcant diﬀerence observed
between the HFD and LFD group supports the procedure
of feeding the HFD to induce impaired insulin sensitivity.
Among the groups of mice that consumed HFD, those that
received at least 3 injections of STZ displayed an even more
pronounced impairment in insulin sensitivity, suggesting
that at least 3 injections of STZ produce a true diabetic
model.
The evaluation of islet mass in this study provides a
direct measure of the eﬀect of STZ and the correlation
to physiological parameters measured. There is a 60%
reduction in relative pancreatic beta cell volume in obese
T2D patients and 40% reduction in obese individuals with
impaired FBG levels [29, 30]. We further evaluated islet
volume and mass in mice that consumed HFD or LFD
and received either the vehicle or 3 injections of STZ to
determine if these doses of STZ are adequate to cause partial
and signiﬁcant β-cell destruction. Three injections of STZ,
regardless of diet, resulted in approximately 50% destruction
of islets, similar to the amount of lost β cells observed in
human T2D. Apparently, destruction of this amount of β
cells in HFD mice, but not in LFD mice, is adequate to cause
diabetes.
There are several explanations for the accentuated
progression to diabetes after STZ injection in mice that
consumed the HFD. The mice that consume the HFD
gradually develop insulin resistance; we demonstrated that
mice consuming the HFD showed impaired insulin sen-
sitivity combined with greater insulin secretion, which is
characteristic of many obese humans. The trigger is then
the destruction of pancreatic β cells, leading to an inability
for residual islets to secrete adequate amounts of insulin to
compensate for insulin resistance. Indeed, the progression
to T2D in humans with obesity is largely due to insulin
secretory dysfunction and signiﬁcant loss of functional β
cells [31]. The chronic feeding of a high-fat diet may result
in metabolic changes that alter the sensitivity of islets to
toxic agents. Or, after ablation of cells by STZ treatment,
remaining cells in mice fed the HFD may be dysfunctional
as compared with the remaining cells in mice that consumed
LFD, further reducing their ability to compensate for insulin
resistance. The latter may be the case since histological
analyses showed that islet mass was similar in mice that
consumed either HFD or LFD and received 3 STZ injections,
and serum insulin levels were diﬀerent, suggesting that
indeed, β-cell dysfunction preceded the full progression to
diabetesinducedbySTZinjections.Inconclusion,byfeeding
a high-fat diet and delivering consecutive low doses of STZ
to older adult mice, we were able to optimize conditions for
establishing a nongenetic and inexpensive mouse model that
more closely mimics the metabolic proﬁle that characterizes
T2D in humans. This mouse model should be appropriate
for future studies aimed at developing methods for T2D
prevention and treatment.
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